Trials / Terminated
TerminatedNCT00769873
Anticoagulation Post Laparoscopic Splenectomy
Effect of Anticoagulation in Reducing the Incidence of Splenic/Portal Vein Thrombosis Post-Laparoscopic Splenectomy Protocol Number: 5698
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 35 (actual)
- Sponsor
- University of Alberta · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Splenic/portal vein thrombosis is an alarming complication of splenectomy. Retrospective studies in the literature have shown the incidence of symptomatic splenic/portal vein thrombosis to be between 0.7% (Rattner et al., 1993) to 8% (Winslow et al., 2002). This is a single-center, prospective, randomized study in subjects undergoing laparoscopic splenectomy. All participants will receive one dose of pre-operative low molecular weight heparin (Lovenox®) subcutaneously, 2 hours prior to surgery. Participants will be randomized pre-operatively to treatment or control group however the treatment allocation will not be revealed until the surgery is complete. Postoperatively, those assigned to the treatment group will receive 40 mg of Lovenox® subcutaneously once a day for 21 days; those in the control group will not. Patients with severe renal impairment will receive an adjusted dose of Lovenox® (30 mg subcutaneous dose daily). All patients will have a baseline abdominal Doppler ultrasound preoperatively and a second one done at 14 to 28 days post surgery to monitor for the presence of portal vein and/or splenic vein thrombosis. They will also have their lipase and liver function tests checked to correlate with the imaging findings.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Enoxaparin | Lovenox 40mg SC daily (30mg SC daily if creatinine clearance \< 30) for 21 days |
Timeline
- Start date
- 2006-10-01
- Primary completion
- 2009-04-01
- Completion
- 2009-05-01
- First posted
- 2008-10-09
- Last updated
- 2009-06-24
Locations
2 sites across 1 country: Canada
Source: ClinicalTrials.gov record NCT00769873. Inclusion in this directory is not an endorsement.